High levels of TNFα in patients with COVID-19 refractory to tocilizumab
Eur J Cancer
.
2021 May:149:102-104.
doi: 10.1016/j.ejca.2021.01.056.
Epub 2021 Mar 20.
Authors
F X Danlos
1
,
F Ackermann
2
,
J Rohmer
2
,
M Roumier
2
,
A Marabelle
3
,
J M Michot
4
Affiliations
1
INSERM U1015, Gustave Roussy Villejuif, France.
2
Hôpital Foch, Suresnes, France.
3
INSERM U1015, Gustave Roussy Villejuif, France; Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address: Aurelien.marabelle@gustaveroussy.fr.
4
Département D'Innovation Thérapeutique et D'Essais Précoces (DITEP), Gustave Roussy, Université Paris Saclay, Villejuif, France.
PMID:
33848711
PMCID:
PMC7980142
DOI:
10.1016/j.ejca.2021.01.056
No abstract available
Publication types
Letter
Comment
MeSH terms
Antibodies, Monoclonal, Humanized
COVID-19 Drug Treatment*
Humans
SARS-CoV-2
Tumor Necrosis Factor-alpha
Substances
Antibodies, Monoclonal, Humanized
Tumor Necrosis Factor-alpha
tocilizumab